Aura Biosciences Inc. is a clinical-stage oncology company developing a novel technology platform based on virus-like drug conjugates to target and destroy cancer cells selectively while activating the immune system. The company's lead product candidate includes AU-011. Aura Biosciences Inc. is based in CAMBRIDGE, Mass.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-86.92M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.60 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -58.63% |
| Return on Assets (Trailing 12 Months) | -49.74% |
| Current Ratio (Most Recent Fiscal Quarter) | 11.06 |
| Quick Ratio (Most Recent Fiscal Quarter) | 11.06 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $3.04 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.55 |
| Earnings per Share (Most Recent Fiscal Year) | $-1.75 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.90 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 50.27M |
| Free Float | 47.55M |
| Market Capitalization | $333.28M |
| Average Volume (Last 20 Days) | 0.24M |
| Beta (Past 60 Months) | 0.42 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 5.40% |
| Percentage Held By Institutions (Latest 13F Reports) | 96.75% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |